Recruiting Clinical Trials

Displaying 21 - 30 of 34 result(s)
Study Title Condition Phase Location
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients IgA Nephropathy Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Australia
  • Country: 
A Randomized, Multi-center, Subject and Investigator-blinded, Placebo-controlled, Parallel-group Study to Assess the Efficacy Safety and Tolerability of LYS006 in Patients With Mild to Moderate Ulcerative Colitis Colitis, Ulcerative Phase 2
  • Country: 
    Bulgaria
  • Country: 
    Czech Republic
  • Country: 
    Germany
  • Country: 
A 56-week Phase IIIb/IV, Open-label, One-arm Extension Study to Assess the Efficacy and Safety of Brolucizumab 6 mg in a Treat-to-Control Regimen With Maximum Treatment Intervals up to 20 Weeks for the Treatment of Patients With Neovascular Age-relat ... Neovascular Age-related Macular Degeneration Phase 4
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Belgium
  • Country: 
A 5-year, Randomized, Double-blind, Placebo-controlled, Multi-center Study Assessing the Efficacy, Safety, and Tolerability of Intra-articular Regimens of LNA043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis Osteoarthritis Phase 2
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    China
  • Country: 
A Randomized, Open-label, Two Arm, Parallel Group, Proof-of-concept Clinical Trial to Investigate the Efficacy and Safety of LNP023 Compared With Rituximab in the Treatment of Subjects With Idiopathic Membranous Nephropathy Glomerulonephritis, Membranous Phase 2
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Czech Republic
  • Country: 
A Placebo-controlled, Patient and Investigator Blinded, Randomized Parallel Cohort Study to Assess Pharmacodynamics, Pharmacokinetics, Safety, Tolerability and Preliminary Clinical Efficacy of VAY736 and CFZ533 in Patients With Systemic Lupus Erythem ... Systemic Lupus Erythematosus (SLE) Phase 2
  • Country: 
    Argentina
  • Country: 
    Australia
  • Country: 
    China
  • Country: 
A Phase II, Open-label, Single Arm Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (PKC412) Combined With Standard Chemotherapy and as a Single Agent Post-consolidation Therapy in Children With Untreated FLT3-m ... FLT3-mutated Acute Myeloid Leukemia Phase 2
  • Country: 
    United States
  • Country: 
    Czech Republic
  • Country: 
    Italy
  • Country: 
A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer, Head and Neck Cancer, DLBCL, Diffused Large B Cell Lymphoma, MSS, Microsatellite Stable Colon Cancer, TNBC, Triple Negative Breast Cancer, Melanoma, mCRPC, Metastatic Castration Resistant Prostate Cancer Phase 2
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Austria
  • Country: 
The Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis Multiple Sclerosis Not Given
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Australia
  • Country: 
A 12-month, Open-label, Multicenter, Randomized, Safety, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of an Anti-CD40 Monoclonal Antibody, CFZ533 vs. Standard of Care Control, in Adult de Novo Liver Transplant Recipients With a 12-mo ... Liver Transplant Rejection Phase 2
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Belgium
  • Country: